Latest News

Professional semiconductor solution provider Spirox Corporation (TWSE: 3055) and NI (Nasdaq: NATI) jointly announce today that they have developed an RF total test solution for product development in labs to mass production to help arQana accelerates the time-to-market of their products. The high flexibility of the NI Semiconductor Test System (STS)and system integration ability of Spirox application engineering team make it possible to decrease the time of cross-check and redevelopment under the strict test specifications.

Professional semiconductor solution provider Spirox Corporation (TWSE: 3055) and Molsentech (Molecular Sensoring Technology Co., Ltd.) announce today that they will soon launch COVID-19 biosensor test system. Based on ultra-high sensitivity biomedical detection technology, Molsentech’s COVID-19 rapid test kit, including a biosensor chip and a test device, can run a rapid test with accurate result in 3 minutes, even in early stage infection or asymptomatic infection. These rapid COVID-19 test system, which will be an important breakthrough for Taiwan and global media system in COVID-19 test, will kick off next stage clinical trial in Kaohsiung Veterans General Hospital (KSVGH), and expectedly to be verified and launch in the end of 2020.

Spirox Corp. (TWSE: 3055), a professional value-added solution provider, announces a strategic investment plan with its vendor partner Wintest Corp. (TYO: 6721), which agreed by the Board yesterday. Spirox will buy 9.09% of Wintest shares at JPY 220 (approx. NTD 62) per share, and Wintest will buy 5~6% of Spirox shares at NTD 40 per share. Spirox and Wintest will develop semiconductor test solutions together to fulfill customer demands resulted from semiconductor localization in the Great China.